Back to search results

Closed Loop Oxygen Control for COPD Patients in the Hospital

This study is looking at a new way to deliver oxygen to people with Chronic Obstructive Pulmonary Disease (COPD) who are in the hospital and having trouble breathing. It compares two methods of using nasal high flow (a type of oxygen therapy): one uses a device called Airvo 3 in OptiO2 mode, which automatically adjusts oxygen, and the other uses manual titration, where oxygen is adjusted by hand. The goal is to see if the Airvo 3 device can keep your oxygen levels (SpO2) within a healthy range better than manual adjustments. You might be able to join if you are 22 or older, have COPD, are in the hospital with breathing difficulties, and are already using or are a candidate for nasal high flow oxygen. The study is currently unclear on its recruitment status and plans to enroll about 70 people.

Study design
This study is an interventional study comparing two different methods of oxygen delivery. It plans to enroll about 70 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your oxygen levels will be monitored for 24 hours to see how well they stay within the target range.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07222410

Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital

Recruiting
NAAges 22+InterventionalTreatment
Fisher and Paykel Healthcare
~70 participants
Updated 2026-06-23 on ClinicalTrials.gov
What's tested:Closed loop oxygen controlManual titration

At a glance

Recruiting sites
4 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of time with SpO2 in target range over period of observation
Measured over 24 hours
+1 more outcome measured

Conditions

COPD

Explore related trials

Chronic Obstructive Pulmonary Disease

Where it's being run

4 sites across 4 states
Alabama1
Iowa1
New York1
Pennsylvania1

Who to contact

Jenny Han
[email protected]
64 9 574 0123
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Has cognitive ability to provide informed consent
Aged 22 years or older
Hospitalized with hypoxemia/respiratory distress
Diagnosis of COPD
Candidate for/currently prescribed nasal high flow (flow rate of at least 25 L/min) with supplemental oxygen, as assessed by the investigator
Expected duration of oxygen and nasal high flow therapy \>24 hours (not necessarily continuous)

Exclusion

Receiving Non Invasive Ventilation (NIV) or indicated for NIV as per European Respiratory Society /American Thoracic Society guidelines
Hemodynamic instability (systolic blood pressure \<90mmHg or requirement for vasopressor or inotropic support)
Patient receiving end of life care
Nasal or facial conditions precluding use of nasal high flow
Pregnancy or breastfeeding
Cognitive impairment or impaired consciousness precluding informed consent
Unsuitable for adhesive finger pulse oximetry, as assessed by the investigator
Any other condition which, at the investigator's discretion, is believed to present a safety risk to the patient if included
The presence of any active comorbidities that affect the patient's condition importantly in the next 30 days, as assessed by the investigator
Has already participated in this clinical trial

What this trial measures

  • Percentage of time with SpO2 in target range over period of observation24 hours
  • Percentage of time with SpO2 out of target range over period of observation24 hours